易瑞生物
(300942)
| 流通市值：25.52亿 | | | 总市值：25.52亿 |
| 流通股本：4.05亿 | | | 总股本：4.05亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 128,365,795.09 | 57,644,102.49 | 263,229,020.8 | 185,633,642.05 |
| 营业总成本 | 154,899,413.61 | 73,515,702.11 | 260,412,512.64 | 181,665,643.9 |
| 其他经营收益 | | | | |
| 营业利润 | -23,862,504.33 | -13,144,924.51 | 5,577,907.93 | 16,671,226.8 |
| 利润总额 | -24,159,286.52 | -13,090,611.36 | 13,288,905.62 | 16,988,453.86 |
| 净利润 | -19,396,770.83 | -10,485,725.7 | 15,466,356.76 | 18,807,119.87 |
| 每股收益 | | | | |
| 其他综合收益 | -444,264.96 | -217,813.54 | 160,162.48 | -108,226.44 |
| 综合收益总额 | -19,841,035.79 | -10,703,539.24 | 15,626,519.24 | 18,698,893.43 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 794,062,586.54 | 798,255,225.43 | 817,814,250.15 | 775,373,728.96 |
| 非流动资产: | | | | |
| 非流动资产合计 | 686,127,769.84 | 689,706,895.03 | 706,733,614.44 | 706,186,305.89 |
| 资产总计 | 1,480,190,356.38 | 1,487,962,120.46 | 1,524,547,864.59 | 1,481,560,034.85 |
| 流动负债: | | | | |
| 流动负债合计 | 120,110,411.25 | 109,458,166.26 | 160,703,352.59 | 150,304,279.47 |
| 非流动负债: | | | | |
| 非流动负债合计 | 479,633,554.94 | 479,082,080.16 | 456,164,030.14 | 420,904,074.09 |
| 负债合计 | 599,743,966.19 | 588,540,246.42 | 616,867,382.73 | 571,208,353.56 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 873,999,669.33 | 893,621,562.52 | 904,080,226.3 | 908,090,377.01 |
| 股东权益合计 | 880,446,390.19 | 899,421,874.04 | 907,680,481.86 | 910,351,681.29 |
| 负债和股东权益合计 | 1,480,190,356.38 | 1,487,962,120.46 | 1,524,547,864.59 | 1,481,560,034.85 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 173,305,931.85 | 81,199,577.14 | 344,052,768.69 | 206,284,991.21 |
| 经营活动现金流出小计 | 179,177,679.38 | 93,727,023.75 | 277,180,954.85 | 198,456,014.85 |
| 经营活动产生的现金流量净额 | -5,871,747.53 | -12,527,446.61 | 66,871,813.84 | 7,828,976.36 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 392,094,880.16 | 110,633,165.49 | 866,005,376.48 | 741,477,443.1 |
| 投资活动现金流出小计 | 354,160,816.37 | 82,314,399.09 | 827,495,842.8 | 586,485,714.74 |
| 投资活动产生的现金流量净额 | 37,934,063.79 | 28,318,766.4 | 38,509,533.68 | 154,991,728.36 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 24,860,781.28 | 24,770,781.28 | 27,328,827.62 | 26,928,827.62 |
| 筹资活动现金流出小计 | 29,663,339.22 | 15,121,932.48 | 54,846,231.04 | 51,094,548.12 |
| 筹资活动产生的现金流量净额 | -4,802,557.94 | 9,648,848.8 | -27,517,403.42 | -24,165,720.5 |
| 汇率变动对现金及现金等价物的影响 | -11,223,441.47 | -6,680,492.72 | 986,297.22 | 3,204,826.71 |
| 现金及现金等价物净增加额 | 16,036,316.85 | 18,759,675.87 | 78,850,241.32 | 141,859,810.93 |
| 期末现金及现金等价物余额 | 352,018,517.59 | 354,741,876.61 | 335,982,200.74 | 398,991,770.35 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 16,036,316.85 | - | 78,850,241.32 | - |